Stay updated on Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.

Latest updates to the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedThe page footer now displays Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision tag updated to v3.4.1, replacing v3.4.0, with no changes to study content or user-facing details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check80 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check101 days agoChange DetectedThe page's Locations section was reorganized into a single 'Locations' block with an expanded list of sites across multiple regions, replacing the prior country/state location headers. The update also includes Revision: v3.3.3.SummaryDifference2%

Stay in the know with updates to Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.